Show simple item record

dc.contributor.authorMatsumoto, Tomoko
dc.contributor.authorMatsumaru, Naoki
dc.contributor.authorScuffham, Paul
dc.contributor.authorNeels, Pieter
dc.contributor.authorTsukamoto, Katsura
dc.date.accessioned2020-07-15T01:45:26Z
dc.date.available2020-07-15T01:45:26Z
dc.date.issued2020
dc.identifier.issn2168-4790
dc.identifier.doi10.1007/s43441-020-00189-1
dc.identifier.urihttp://hdl.handle.net/10072/395408
dc.description.abstractBackground: The human papillomavirus (HPV) vaccine coverage is very low in Japan since the government suspended the active encouragement of the vaccination. We aimed to conduct a benefit–risk assessment of HPV vaccination and explore different consequent scenarios to identify potential improvements to the current Japanese immunization program. Methods: To calculate social benefit–risk of HPV vaccine, we used the Markov model to represent the natural history of HPV and adverse events (AEs) using disability-adjusted life year (DALY) as the outcome. Benefits and risks were calculated as the sum of negative and positive outcomes corresponding to all preventable diseases and AEs associated with HPV vaccination, respectively. The benefit–risk balance in 2050 was estimated using published data. Results: Our model was confirmed by published cervical cancer incidence and mortality rates. The benefit–risk balance in 2050 showed that the most effective scenario was the introduction of 9-valent HPV vaccine targeting female individuals aged 10–29 years for routine vaccination starting in 2020, although there is possibility of increased risks of AEs for the vaccinated age group post resumption of recommendations. Conclusion: Our benefit–risk assessment of HPV vaccine helped estimate various scenarios pertaining to HPV vaccination and identify the best strategy regarding HPV vaccination. This benefit–risk assessment approach may be used for other vaccines and vaccination programs.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofjournalTherapeutic Innovation and Regulatory Science
dc.subject.fieldofresearchStatistics
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchHealth services and systems
dc.subject.fieldofresearchPublic health
dc.subject.fieldofresearchcode4905
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode4203
dc.subject.fieldofresearchcode4206
dc.subject.keywordsBenefit–risk assessment
dc.subject.keywordsDisability-adjusted life years (DALY)
dc.subject.keywordsDisease burden
dc.subject.keywordsHPV
dc.subject.keywordsVaccine decision-making
dc.titleAlternative New Mono-scaled Quantitative Benefit–Risk Assessment of Human Papillomavirus Vaccine in Japan
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationMatsumoto, T; Matsumaru, N; Scuffham, P; Neels, P; Tsukamoto, K, Alternative New Mono-scaled Quantitative Benefit–Risk Assessment of Human Papillomavirus Vaccine in Japan, Therapeutic Innovation and Regulatory Science, 2020
dcterms.dateAccepted2020-06-11
dc.date.updated2020-07-15T01:38:10Z
gro.description.notepublicThis publication has been entered in Griffith Research Online as an advanced online version.
gro.hasfulltextNo Full Text
gro.griffith.authorScuffham, Paul A.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record